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A Mass-Spectrometry-Based Modelling Workflow for Accurate
Prediction of IgG Antibody Conformations in the Gas Phase
Kjetil Hansen+, Andy M. Lau+, Kevin Giles, James M. McDonnell, Weston B. Struwe,
Brian J. Sutton, and Argyris Politis*
Abstract: Immunoglobulins are biomolecules involved in
defence against foreign substances. Flexibility is key to their
functional properties in relation to antigen binding and
receptor interactions. We have developed an integrative
strategy combining ion mobility mass spectrometry (IM-MS)
with molecular modelling to study the conformational dynam-
ics of human IgG antibodies. Predictive models of all four
human IgG subclasses were assembled and their dynamics
sampled in the transition from extended to collapsed state
during IM-MS. Our data imply that this collapse of IgG
antibodies is related to their intrinsic structural features,
including Fab arm flexibility, collapse towards the Fc region,
and the length of their hinge regions. The workflow presented
here provides an accurate structural representation in good
agreement with the observed collision cross section for these
flexible IgG molecules. These results have implications for
studying other nonglobular flexible proteins.
Immunoglobulins (Ig), or antibodies, are the proteins
responsible for mediating an extensive network of immuno-
logical responses. The past decades have seen a steady
increase of interest in developing Igs as biotherapeutic
agents for the treatment of various diseases, including
cancer and autoimmune disorders.[1–3] While the architectures
of Igs are relatively conserved, they exhibit dramatic differ-
ences in their dynamics and mode of interactions with
antigens and cognate receptors.[4, 5] These differences stem
from intrinsic features in their structures such as binding-site
specificity and hinge flexibility (Figure 1a).[6]
There are five isotypes or classes of Igs, the most abundant
of which in humans is Ig gamma (IgG), comprising approx-
imately 75% of all human antibodies in serum.[7] IgG is by far
the most commonly exploited isotype for biotherapeutics,[1]
including bispecific antibodies[8, 9] and antibody–drug conju-
gates (ADCs).[10–12] In 2017, ten new antibody therapeutics
were approved, all of which were IgG-based.[13] There are four
subclasses of human IgG, named IgG1–4 (Figure 1a). While
IgG1, 2, and 4 are similar in topology, overall length, and
hinge length, IgG3 has a markedly longer hinge, producing
a molecule much longer than the other subclasses.[14, 15] IgG
molecules exhibit a high degree of heterogeneity because of
their extensive glycosylation, and also sequence variability in
their antigen binding regions. All IgG molecules consist of
two heavy chains and two light chains that are covalently
linked via disulphide bridges in a characteristic “Y” shaped
topology (Figure 1b). A central hinge separates two Fab
“arms” from the Fc “stem” of the IgG molecule. This hinge
plays a pivotal role in providing IgGmolecules with flexibility,
allowing relative Fab–Fab and Fab–Fc movements.[16] The
hinge and Fc region play an important role in binding immune
effector proteins including, the Fc gamma receptors (FcgR),
neonatal Fc receptor (FcRn), and complement component
C1q[14] (Figure 1). The ability for all IgG subclasses except
IgG4 to trigger the complement cascade via C1q,[17] for
example, illustrates that the intrinsic structure and dynamics
of these molecules have functional consequences for each of
the IgG subclasses.
Native mass spectrometry (MS) has recently emerged as
a powerful method for interrogating proteins and their
complexes, providing valuable information about their stoi-
chiometry and topology.[18–25] Native MS can be hyphenated
with IM; the resulting ion mobility (IM)-MS method offers an
extra dimension enabling shape information on the inves-
tigated proteins. IM-MS allows for derivation of topological
information of proteins through calculating their collisional
cross section (CCS). CCS is described as the rotationally
averaged cross section of a molecule and is calculated based
on the overall size and molecular architecture.[26] The
experimentally measured CCS can be compared to theoret-
ical CCS calculated from structural models derived by
molecular dynamics (MD) simulations or other modelling
techniques,[27,28] thus enabling structures to be assigned back
to experimental observations.[29]
Native MS mainly uses electrospray ionisation (ESI) for
the purpose of creating multiply charged protein ions.[30] The
response of folded proteins entering the gas phase through
ESI is most commonly described through the charged residue
model (CRM).[31–33] The CRM envisions gradual droplet
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desolvation leading to production of a dry protein ion. While
the behaviour of a globular protein transferring into the gas
phase of a mass spectrometer can be rationalised under the
CRM framework, here we pose the following question: do
these same rules apply to nonglobular and flexible proteins?
Early studies which compared the experimental CCS of
antibodies to those calculated from their crystal structures,
observed a greater than 30% discrepancy between these CCS
values,[34, 35] thus suggesting collapse of the protein in the gas
phase. Such collapse is experienced by nonglobular molecules
that are intrinsically flexible or disordered in solution and are
capable of conformational change.[36–39] Whilst others have
explored simulating such collapsing structures,[37] these call
for computationally complicated methods such as “trajectory
stitching”[40] or including mobile proton algorithms,[41,42]
which may be impractical for large molecules. Here, we
have developed an integrative IM-MS-based strategy that
enables the prediction of the structure and dynamics of IgG
molecules in the gas phase, including, for the first time,
capturing and simulating the dynamics of human IgG3
(Figure 1a–c). In the first step, homology models of the
antibodies were built and subsequently subjected to Fab arm
sampling, allowing representation of their intrinsic flexibility
as a conformational ensemble. Simultaneously, we subjected
IgG1–4 to IM-MS experiments and derived their correspond-
ing CCS values. The most compact conformations were taken
forward for vacuum MD simulations in order to model the
gas-phase structure of IgG molecules.
The flexible nature of IgG molecules means that there are
currently only four intact IgG crystal structures available:
IgG1 (human: 1HZH, mouse: 1IGY),[43,44] IgG2 (mouse:
1IGT)[45] and most recently, IgG4 (human: 5DK3).[46] We
modelled human IgG1, 2, and 4 using the available crystal
structures, followed by generation of any missing residues
(see Methods in the Supporting Information). IgG3, however,
presented a greater challenge resulting from its complex
hinge structure and lack of crystallographic representation.
The absence of an IgG3 intact crystal structure is likely due to
its greater flexibility. We thus built a homology model of
human IgG3 and subjected it to 100 ns of explicit solvent
simulation to model its average solution state conformation
(Supplementary Figure 3, Methods). This average conforma-
tion exhibits a hinge length of approximately 70c between
the Fab and Fc regions, with the fully extended length of the
hinge at approximately 110 c (Supplementary Figure 4). This
is in agreement with an earlier electron microscopy study by
Roux et al. who observed a distance of (80: 23) c between
the Fabs and Fc in solution, and an estimated 100–110c for
the length of the extended hinge,[6] as well as with other
hydrodynamic and solution X-ray scattering studies.[47,48]
We next subjected all four of the human IgG subclasses to
IM-MS, which allowed us to quantify their topology through
their experimental CCS values (Figure 2a, Supplementary
Figures 5,6, and Table 1). Consistent with previous studies of
human IgG1–4,[34,35] we observed an approximately 30%
difference between the experimental CCS (CCSexp) and
model CCS (CCSmodel ; Table 1), thus suggesting significant
structural collapse. Despite the much longer length of IgG3
compared to IgG1, 2, and 4, all IgG antibodies are equally
able to collapse, producing a CCS of approximately 7000c2.
We further deglycosylated all antibodies and subjected them
to IM-MS (Supplementary Figures 7,8)—the resulting CCS
showed no significant difference compared to their glycosy-
lated counterparts (< 1%; Supplementary Figure 9 and
Methods). To further exclude the possibility that glycoform
heterogeneity influences IgG gas-phase conformations, we
characterised the glycans bound to two additional monoclonal
antibodies, Herceptin and Waters mAb, and compared their
glycoforms to Sigma IgG1 (Supplementary Figure 10 and
Methods). While we identified different N-linked glycans
bound to the IgG molecules, their corresponding CCS values
were found to be within 1%, thus indicating no significant
changes in their conformations.
The ability of significant compaction is likely provided by
IgG hinges imparting the steric freedom necessary for the Fab
and Fc domains to contort into a compact structure. While
Figure 1. Schematics and workflow for modelling antibody flexibility. a) Schematic representation of human IgG1–4 subclasses. b) Representative
structure of IgG1, denoting hinge substructure and modes of Fab movement stemming from the upper hinge. c) Integrative workflow generating
and comparing the calculated CCS values of initial, post-sampling, and gas-phase MD models with experimental CCS values.
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collapse of IgG structures and other flexible molecules in the
gas phase have been widely observed, simulating their
collapsed structures remains a challenge. Previous studies
beginning gas phase simulations directly from crystal struc-
tures of IgG molecules, show more than 20% discrepancy
from their CCSexp values.
[34, 35] Thus, we hypothesise that IgG
molecules may experience precollapse prior to transfer into
the gas phase.
With the aim of developing a methodology able to
simulate the collapse of IgG molecules, we designed an
in silico workflow for pairing experimental data with compu-
tational models (Figure 1c). In the first step of our modelling
workflow, we subject each of the four initial IgG models to
Fab arm conformational sampling using a rapidly exploring
random tree algorithm (see Methods in the Supporting
Information). This sampling technique produces randomly
Figure 2. Modelling the conformational flexibility of antibodies. a) Representative mobilogram and native mass spectrum (i) and CCS distributions
for 21–23+ charge states of IgG2 (ii). b) Space occupied by IgG1–4 Fabs following upper-hinge flexibility sampling. Each sphere represents one
model for each IgG Fab heavy chain (teal and purple). Light chains are shown as blue. Initial models are shown as surface representations.
c) Overlay of experimental CCS distribution with triplicate simulated collapse models. Experimental error is represented by the :6% dotted lines.
Purple error bars represent the CCS range over the last 1 ns of gas-phase simulation.
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varied Fab conformations given the degrees of freedom
allowed by the antibodyQs flexible upper hinge residues.
Specifically, the conformations of residues between the most
N-terminal hinge disulphide bond and the Fab domains are
explored. Sampling in this way produces a model ensemble of
conformations of IgG structures which mimic their flexibility
in a solution environment.
Through Fab arm sampling, we generated 10000 con-
formations for each IgG and calculated the model variation
over each ensemble (Figure 2b, Table 1, Supplementary
Figures 11,12). The CCS variation in each of the IgG
ensembles correlated well with previously reported Fab
flexibility (IgG3> IgG1> IgG4> IgG2)[6, 49] and upper-hinge
lengths. Closer inspection of the conformational space
occupied by each Fab arm revealed that Fabs of IgG1, 2,
and 4 are restricted to their own hemispheres (Figure 2b).
The Fabs of IgG3 however, share a high degree of overlapping
space indicative of their enhanced flexibility provided by the
longer upper-hinge region (Figure 2b).
Our sampling strategy identified conformations of IgG1
that are highly similar to those modelled through solution-
based small-angle X-ray scattering (SAXS).[50] A recent study
also highlighted the ability of Fab arm sampling and clustering
analysis to deliver solution-relevant antibody conforma-
tions.[51]Within our IgG2 ensemble, movement of Fab arms
are more confined due to the presence of two extra disulphide
bonds located in the upper hinge compared to the other short
IgGmolecules (IgG1 and IgG4; Table 1). While Fabs of IgG1,
IgG3, and IgG4 are able to flex away from their Fc, exposing
potential receptor binding sites (Supplementary Figure 1),
this dynamic behaviour is not shared to such a degree by
IgG2. It is interesting to speculate that this modelling
observation may offer insight into why experimentally, IgG2
exhibits reduced affinity to some FcgR receptors compared to
IgG1, 3, and 4.[14, 52]
While Fab arm sampling provides a powerful method of
exploring the conformational space, it is important to note
that this is a pseudosimulation and does not take the energetic
landscape of the molecule into account. To provide structures
relevant to the gas-phase environment, we subjected models
from each ensemble to molecular dynamics (MD) in vacuo
(Supplementary Figures 13–16, Methods). We performed
simulations in triplicates by selecting the lowest CCS and
two low CCS models from each Fab arm sampling ensemble.
Each model was precharged with the lowest observed
experimental charge state (Table 1). The models were then
simulated in vacuo for 10 ns (Methods). All CCSmodel calcu-
lated for the final simulation frame for each IgG were within
approximately 6% of the CCSexp values, with the closest
match being IgG3 showing 0.1% CCS difference. For each set
of three simulations, the CCS difference between independ-
ent simulations were 3.8% for IgG1, 1.9% for IgG2, 4.3% for
IgG3, and 4.9% for IgG4. We additionally carried out
simulations of IgG4 for charge states 22–25+ which show
agreement with experimental values (Supplementary
Figure 17). To the best of our knowledge, this is the first
time that the dynamic structures of substantially collapsed
IgG molecules have been modelled with this level of agree-
ment with experimental values. Overlaying the CCSmodel of
our collapsed models with the experimental CCS distribution
showed that each individual simulation occupies a narrow
CCS range, thus indicating that collapsed structures are
relatively inflexible in the gas phase (Figure 2c). We hypothe-
sise that IgG flexibility in solution leads to a diverse
population of rigid collapsed structures in the gas phase,
resulting in the observed experimental CCS distribution. The
Table 1: Experimental and modelling values for IgG1–4.
Subclass[a] IgG1 IgG2 IgG3 IgG4
Theoretical mass [kDa][a] 150 150 170 150
Experimental mass [Da][b] 149328(:89) 154297(:42) 162123(:4) 155758(:62)
Experimental charge[c] 21+ 21+ 22+ 21+
Overall hinge length[d] 12 12 62 12
No. hinge disulphides 2 4 11 2
Upper hinge residues sampled 5 3 12 7
Initial model CCS [b2][e] 9532 9747 10958 9512
Fab arm sampling CCS [b2][f ] 8756 8597 9170 8484
DCCS of sampling [b2][g] 1102 929 1329 1080
Collapsed model CCS [b2][h]
Model 1 7226(:176) 7396(:201) 7284(:173) 7017(:204)
Model 2 6988(:196) 7197(:184) 7176(:197) 6766(:268)
Model 3 7142(:176) 7309(:213) 7588(:202) 6644(:179)
Experimental CCS [b2][i] 6827(:81) 7030(:113) 7173(:68) 7024(:97)
Deglycosylated CCS [b2][j] 6851(:61) 7087(:56) 7202(:43) 7095(:51)
Net solution charge[k] 20+ 2@ 2+ 2+
[a] Approximate mass of glycosylated protein given sequence variability in Fc and Fab regions. [b] Experimentally observed glycosylated mass fromMS
(: standard deviation). [c] Lowest observed experimental charge for glycosylated proteins. [d] Fc to Fab distances (Uniprot: IgG1 P01857, IgG2
P01859, IgG3 P01860, IgG4 P01861). [e] CCS=PAW1.14 calculated by IMPACT for starting models. [f ] Lowest CCSmodel generated from Fab arm
sampling. [g] CCSmodel range of ensemble from Fab arm sampling. [h] CCSmodel for triplicate models following 10 ns of gas-phase simulation (: denotes
CCSmodel range over final 1 ns). [i] Average CCS for lowest charge over T-waves 550, 600, and 640 ms
@1 (: standard deviation) for glycosylated proteins.
[j] Average CCS for lowest charge over T-waves 550, 600, and 640 ms@1 (: standard deviation) for deglycosylated proteins. [k] Net solution charge of
each IgG molecule as determined from the Protparam webserver (Supplementary Figure 2).
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results of each step of our modelling workflow has been
summarised in Figure 3.
Our modelling workflow has generated collapsed models
of IgG1–4 that closely match experimental CCS values. The
steps undertaken aim to simulate the collapse of these
molecules in the gas phase whilst remaining consistent with
the current consensus of the CRM of folded proteins under-
going ESI. The timeline emerging from our workflow
envisions that IgG molecules, being flexible in their solution
environments, are coerced into semicollapsed conformations
by their shrinking droplets. This theory is supported by an
MD study which saw gradual desolvation of ubiquitin,
cytochrome c, and holo-myoglobin trajectories over periods
longer than 100 ns.[40]While IgG semicollapsed conformations
are accessible through Fab arm sampling, this procedure
provides two additional benefits. Firstly, computational time-
scales can be cut significantly as the IgG has already collapsed
to mimic a state in which nearly all of the solvent molecules
have already evaporated from the protein. As a result, our
gas-phase MD simulations converge after a much shorter
period of time. Secondly, charges cannot be misassigned to
surfaces of the protein which later form the collapsed
interfaces (which would prevent collapse). Therefore, we
speculate that CRM charge transfer occurs concurrently or
after partial collapse resulting in charge migration from
solvent to exposed protein surfaces. This hypothetical model
has been summarised in Figure 4.
Probing the conformational dynamics of antibodies by
IM-MS has led to several interesting conclusions because of
their intrinsic flexibility. Firstly, the flexibility of IgG mole-
cules can be represented through Fab arm sampling and allow
inferences to be made about their solution dynamics. Building
on these solution-relevant conformations, we theorized that
IgG molecules undergo partial collapse in solution, which
eventually leads to their collapsed topologies in the mass
spectrometer. The ability to model these collapsed structures
accurately has provided insight into the experimental CCS
distribution of these flexible molecules.
In conclusion, this study highlights the need for a pre-
dictive model when interpreting gas-phase data as non-
globular proteins are unlikely to retain their native structures.
A combination of high throughput IM-MS and molecular
modelling may therefore provide complementary structural
and dynamical information to other biologically relevant
techniques such as hydrogen deuterium exchange mass
spectrometry. Such approaches may facilitate invaluable
data interpretation which might not be possible without
structural representations. Ultimately, we anticipate that this
workflow will be applicable to other flexible proteins
currently eluding solution or gas-phase structural and dynam-
ical characterization.
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Figure 4. Proposed collapse pathway of IgG during ESI. a) IgG molecules exhibit full flexibility in solution. b) Nanospray ESI produces charged
droplets in which IgG molecules retain partial flexibility depending on droplet size. c) Gradual evaporation of droplets coerces flexible IgG
molecules into more compact topologies. Solvent charges migrate to protein surfaces as they become exposed through desolvation (CRM).
d) Dry protein ions are inflexible in vacuum and represent a distribution of compact conformations.
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